Navigation Links
Watson Receives FDA Approval for Generic Cardizem(R) LA
Date:3/15/2010

MORRISTOWN, N.J., March 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. – Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, the generic equivalent to Biovail Laboratories International SRL's Cardizem® LA product.  Watson intends to launch its generic version of Cardizem® LA immediately.  

Diltiazem Hydrochloride Extended-Release tablets are indicated for the treatment of hypertension.  For the 12-months ending December 31, 2009, Cardizem® LA had total U.S. sales of approximately $94.1 million, according to IMS Health.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)

SOURCE Watson Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.watson.com

'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
2. Watson Announces Actos(R) Patent Challenge Settlement
3. Watson Confirms Filing of Generic Opana(R) ER Application
4. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
5. Watson to Present at CLSA/Asia USA Investors Forum
6. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
7. Watson Completes Acquisition of Eden Biodesign
8. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
9. Watson Files FDA Application for Generic Rozerem(R)
10. Watson to Present at Credit Suisse Healthcare Conference
11. Watson and Barr Settle Lawsuit Over Oxytrol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb 21, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The Global ... around 12.3% over the next decade to reach approximately $4.5 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/21/2017)... Feb. 21, 2017 Centurion Medical Products, ... patient care, is making a major stride in ... of its IRIG-8™Wound Irrigation System . ... quickly deliver copious volumes of irrigation solution to ... is a significant improvement to the traditional syringe ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a ... and spend management, today announced that Keppel Corporation has selected Apptricity Travel and ... , “We are excited to announce the partnership between Keppel and Apptricity ...
(Date:2/21/2017)... ... 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... the keynote speaker at its second Professional Networking Breakfast on March 9, 2017. ... comprehensive strategies to create and expand opportunities for boys and young men of ...
(Date:2/21/2017)... ... ... Support of value-based care models requires collaboration across all facets of the ... Fogo Data Centers announces the launch of the Fogo Partner Community™. , At Fogo, ... which all systems work well, work together, and work together well. In healthcare, ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... the rate at which women are called back for additional examinations without sacrificing ... Radiology . , In 2011, the U.S. Food and Drug Administration approved digital ...
Breaking Medicine News(10 mins):